^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Kidney Cancer

    Related cancers:
    1d
    Novel Nanopore-Based Copy Number Analysis for Ultrafast Renal Tumor Classification (AMP 2024)
    In this study, we applied the iSCORED pipeline for ultrafast, genome-wide CNV information of renal tumors with results showing complete concordance with established CNV analysis methods. This method could facilitate pathological diagnosis and potentially inform targeted treatment in less than 2 hours. Future directions include expanding analyzed tumor types and integrating methylation classification into the pipeline.
    OncoScan™ CNV Assay • TruSight Tumor 170 Assay
    2d
    DENALI-1: A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression (clinicaltrials.gov)
    P1/2, N=240, Not yet recruiting, A2 Biotherapeutics Inc.
    New P1/2 trial
    5d
    Research on the remote surgical service mode and product configuration scheme of domestic laparoscopic surgical robot system (ChiCTR2400089700)
    P=N/A, N=60, Not yet recruiting, The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University
    New trial
    5d
    Analysis of Risk Factors for the Formation of Special Subtypes in Renal Cancer with Inferior Vena Cava Tumor Thrombus and Evaluation of the Prognosis of Surgical Strategies Based on the 301 Classification and Typing System (ChiCTR2400089772)
    P=N/A, N=225, Not yet recruiting, Chinese PLA General Hospital; Chinese People's Liberation Army (PLA) General Hospital
    New trial
    5d
    Analysis of Risk Factors for Preoperative Renal Insufficiency in Patients with Renal Cancer Accompanied by Inferior Vena Cava Tumor Thrombus (ChiCTR2400089649)
    P=N/A, N=350, Not yet recruiting, Chinese PLA General Hospital; Chinese PLA General Hospital
    New trial
    7d
    CD70-targeted immunoPET Imaging of Kidney Cancer (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, RenJi Hospital
    New trial
    |
    CD70 (CD70 Molecule)
    |
    CD70 expression
    7d
    Comprehensive Pan-Cancer Analysis of the Prognostic Role of KLF Transcription Factor 2 (KLF2) in Human Tumors. (PubMed, Onco Targets Ther)
    Immunohistochemistry and qPCR confirmed the low expression of KLF2 in STAD (stomach adenocarcinoma) and renal cancer. Our pan-cancer analysis provides a comprehensive overview of the oncogenic roles of KLF2 in multiple human cancers and can be regarded as a potential prognostic marker and a novel target for cancer immunotherapy.
    Journal • IO biomarker • Pan tumor
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    7d
    SARS-CoV-2 nucleocapsid protein interaction with YBX1 displays oncolytic properties through PKM mRNA destabilization. (PubMed, Mol Cancer)
    Our study reveals a new function of SARS-CoV-2 nucleocapsid protein on tumor progression.
    Journal
    |
    YBX1 (Y-Box Binding Protein 1) • G3BP1 (G3BP Stress Granule Assembly Factor 1) • PKM (Pyruvate Kinase M1/2)
    8d
    SMARCB1-deficient renal medullary carcinoma with an EML4::ALK fusion gene in a Japanese woman. (PubMed, Pathol Int)
    Six cycles of the dose-dense methotrexate, vinblastine, adriamycin, and cisplatin-combined chemotherapy were completed after an ultrasound-guided percutaneous biopsy of the renal tumor. After chemotherapy, the size of the original tumor in the right kidney had decreased in size, as well as the other metastatic lesions.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • EML4 (EMAP Like 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1)
    |
    ALK fusion • SMARCB1 mutation
    |
    cisplatin • doxorubicin hydrochloride • methotrexate • vinblastine
    8d
    TFE3-Rearranged Renal Cell Carcinoma With Osseous Metaplasia: A Case Report of a Rare Entity With an Unusual Finding. (PubMed, Cureus)
    Osseous metaplasia is an uncommon morphological finding in this particular subtype, and it has been reported in two cases in the literature. We describe the third case of TFE3-rearranged renal cell carcinoma with osseous metaplasia in a healthy 13-year-old male, presenting with worsening abdominal pain and hematuria.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    8d
    C-reactive Protein-albumin-lymphocyte Index as a Novel Biomarker for Progression in Patients Undergoing Surgery for Renal Cancer. (PubMed, Cancer Diagn Progn)
    In addition to the existing risk factors for RCC recurrence, such as sarcomatoid features and Fuhrman grade, we propose that the CALLY index is a predictor of postoperative recurrence and that patients with a low CALLY index are good candidates for postoperative treatment. Our study may help select patients with pT3 disease with a high risk of recurrence who require postoperative treatment.
    Journal • Surgery
    |
    CRP (C-reactive protein)
    |
    Albumin-L
    8d
    NCI-2012-01247: Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer (clinicaltrials.gov)
    P1/2, N=51, Active, not recruiting, Roswell Park Cancer Institute | Trial completion date: Jan 2025 --> May 2025 | Trial primary completion date: Jan 2025 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Avastin (bevacizumab) • pazopanib
    9d
    GO39733: A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors (clinicaltrials.gov)
    P1, N=272, Active, not recruiting, Genentech, Inc. | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Nov 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR negative
    |
    Tecentriq (atezolizumab) • autogene cevumeran (RG6180)
    9d
    Vorolanib in the Second-line Treatment of Patients with Unresectable or Metastatic Renal Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=39, Recruiting, Jinling Hospital, China
    New trial • Metastases
    |
    Fumena (vorolanib)
    10d
    Stereotactic Magnetic Resonance Guided Radiation Therapy (clinicaltrials.gov)
    P=N/A, N=397, Recruiting, Dana-Farber Cancer Institute | Suspended --> Recruiting
    Enrollment open
    10d
    Complete response to fifth-line anti-PD-1 rechallenge in fumarate hydratase-mutated papillary renal cell carcinoma. (PubMed, NPJ Precis Oncol)
    Here, we present the 10-year follow-up of a heavily pre-treated patient with several lines of therapy, achieving a remarkable complete response to anti-PD-1 rechallenge. In addition, we highlight a common immune-related adverse event of anti-PD-1, eosinophilia, as a possible biomarker of response and using TCGA data analysis, provide proof-of-concept for tumor expression of the eosinophil-related gene SIGLEC8, as a promising powerful predictor of prognosis for papillary renal cell carcinoma patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    FH (Fumarate Hydratase) • SIGLEC8 (Sialic Acid Binding Ig Like Lectin 8)
    |
    FH mutation
    10d
    Identifying causal relationships between 35 blood and urine biomarkers and urologic cancers: MR-meta combined with Bayesian colocalization Mendelian randomization analysis. (PubMed, Discov Oncol)
    This study identified significant biomarkers associated with urological cancers in blood and urine. These include GGT, IGF 1, and Lp(a), which are strong biomarkers for PCa. In addition, the findings of this study provide evidence for a handful of risk and protective factors for the development of urologic cancers.
    Journal • Causal relationship
    |
    IGF1 (Insulin-like growth factor 1)
    11d
    A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer (clinicaltrials.gov)
    P=N/A, N=400, Not yet recruiting, Pfizer | Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: May 2025 --> Aug 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    Zirabev (bevacizumab-bvzr)
    11d
    Multinucleated tumor cells and micropapillary morphology appear to be predictors of poor prognosis in renal cell carcinoma with papillary and oncocytic features. (PubMed, Hum Pathol)
    RCC-PO are cytogenetically heterogeneous with overlapping features of various renal neoplasms. Micropapillary features and MTC appear to be independent predictors of poor outcomes in these tumors.
    Journal • Tumor cell
    |
    ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • FLCN (Folliculin) • CTSK (Cathepsin K)
    12d
    Mitochondrial respiratory complex II is altered in renal carcinoma. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    Our findings suggest that the state of CII, epitomized by its assembly and SDHB levels, deteriorates with the progressive severity of ccRCC. These observations hold the potential for stratification of patients with worse prognosis and may guide the exploration of targeted therapeutic interventions.
    Review • Journal
    |
    SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • CA9 (Carbonic anhydrase 9)
    |
    CA9 expression
    13d
    The future of cellular therapy for the treatment of renal cell carcinoma. (PubMed, Expert Opin Biol Ther)
    So far, areas of greater therapeutic success of adoptive cell therapies include the adjuvant administration of CIK cells and the transfer of anti-CD70 CAR T cells in patients with metastatic RCC. Bench to bedside and back research will be needed to overcome current limitations of adoptive cell therapies in RCC, primarily aiming at improving the safety of immune cell products, optimizing their antitumor activity and generating off-the-shelf products ready for clinical use.
    Review • Journal
    |
    CD70 (CD70 Molecule)
    13d
    A framework for target discovery in rare cancers. (PubMed, bioRxiv)
    Finally, we applied our model to predict gene dependencies in tumors from the TCGA (11,373 tumors; 28 lineages) and multiple additional rare cancers (958 tumors across 16 types, including 13 distinct subtypes of kidney cancer), nominating potentially actionable vulnerabilities in several poorly-characterized cancer types. Our results couple unbiased functional genetic screening with a predictive model to establish a landscape of candidate vulnerabilities across cancers, including several rare cancers currently lacking in potential targets.
    Journal
    |
    MCL1 (Myeloid cell leukemia 1) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    |
    TFE3 translocation
    14d
    Avelumab reduces STAT3 expression with effects on IL-17RA and CD15. (PubMed, Dent Med Probl)
    Our study suggests that the targeting of PD-L1 with avelumab alters the expression of CD15 and IL-17RA, which play an important prognostic and therapeutic role in novel anticancer therapy.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3) • IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A) • FUT4 (Fucosyltransferase 4)
    |
    PD-L1 expression • STAT3 expression
    |
    Bavencio (avelumab)
    15d
    NKT2152-202: Ph2 Study NKT2152 with Palbociclib & Sasanlimab in Subjects with Advanced Clear Cell Renal Cell Carcinoma (ccRcc) (clinicaltrials.gov)
    P2, N=172, Active, not recruiting, NiKang Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Jun 2026 | Trial primary completion date: Jun 2026 --> Jun 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Ibrance (palbociclib) • sasanlimab (PF-06801591) • NKT2152
    16d
    Profiling of the serum MiRNAome in pediatric egyptian patients with wilms tumor. (PubMed, Front Mol Biosci)
    Its target genes were enriched in pathways related to cell division and cell cycle regulation. In conclusion, hsa-miR-1180-3p could be a reliable blood-based biomarker for distinguishing WT histopathological types, and further research is needed to validate its clinical value.
    Journal
    |
    MIR7 (MicroRNA 7) • MIR378A (MicroRNA 378a) • MIR483 (MicroRNA 483)
    16d
    NeoVax Plus Ipilimumab in Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Patrick Ott, MD, PhD | Trial completion date: Sep 2026 --> May 2030
    Trial completion date
    |
    Yervoy (ipilimumab) • Neo Vax (NEO-PV-01)
    16d
    Prognostic implications and diagnostic significance of TFE3 rearrangement in renal cell carcinoma. (PubMed, World J Urol)
    TFE3 rearrangement is an independent prognostic factor for recurrence and contributes to a worse PFS, suggesting the necessity of careful follow-up. Diagnosis should be confirmed using FISH due to low specificity of IHC. Further studies are needed to confirm TFE3 IHC staining as a prognostic factor.
    Retrospective data • Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    16d
    Hypoxia-inducing transcription factors: architects of tumorigenesis and targets for anticancer drug discovery. (PubMed, Transcription)
    Significant strides have also been made in the development of direct inhibitors of HIF-2, exemplified by the FDA approval of Belzutifan for the treatment of metastatic clear cell renal carcinoma. While efforts to target HIF-1 using various therapeutic modalities have shown promise, no clinical candidates have yet emerged. This review aims to provide insights into the intricate and extensive role played by HIFs in cancer, and the ongoing efforts to develop therapeutic agents against this target.
    Review • Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit)
    |
    Welireg (belzutifan)
    17d
    Low-Dose-Rate Brachytherapy Combined With Immune Checkpoint Inhibition in Cancer (clinicaltrials.gov)
    P1/2, N=15, Recruiting, Case Comprehensive Cancer Center | Trial completion date: Mar 2025 --> Sep 2025 | Trial primary completion date: Dec 2024 --> Jun 2025
    Trial completion date • Trial primary completion date • Checkpoint inhibition
    17d
    Comparative Proteomics of ccRCC Cell Lines to Identify Kidney Cancer Progression Factors. (PubMed, Cancer Genomics Proteomics)
    From the global proteomics data detected in ccRCC, we propose 99 DEPs including vimentin as progression factors.
    Clinical • Preclinical • Journal
    |
    VIM (Vimentin)
    17d
    Allosteric inhibition of the tyrosine phosphatase SHP2 enhances the anti-tumor immunity of interferon α through induction of caspase-1-mediated pyroptosis in renal cancer. (PubMed, Int Immunopharmacol)
    Allosteric inhibition of SHP2 by SHP099 also potently enhanced the anti-tumor immunity induced by IFNα by modulating T cell proliferation and infiltration in vitro and in vivo. These results reveal the new function of SHP2 in NLRP3 inflammasome activation and pyroptosis in RCC and provide a basis for further investigating the combination of allosteric SHP2 inhibitors with IFNα in cancer immunotherapy.
    Journal • IO biomarker
    |
    IFNA1 (Interferon Alpha 1) • NLRP3 (NLR Family Pyrin Domain Containing 3) • CASP1 (Caspase 1)
    |
    SHP099
    17d
    ZSTK474 targeting PIK3R3 inhibits the Wilms' tumor through G0 / G1 phase arrest. (PubMed, PLoS One)
    This research provides insight into the potential of ZSTK474 and other PI3K inhibitors for treating nephroblastoma.
    Journal
    |
    CDK4 (Cyclin-dependent kinase 4) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • PIK3R3 (Phosphoinositide-3-Kinase Regulatory Subunit 3)
    |
    OP-11
    18d
    STRIKE: Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (clinicaltrials.gov)
    P3, N=1040, Not yet recruiting, Alliance for Clinical Trials in Oncology
    New P3 trial
    |
    Keytruda (pembrolizumab) • Fotivda (tivozanib)
    18d
    Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study (clinicaltrials.gov)
    P3, N=1175, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)
    18d
    Histone-Lysine N-Methyltransferase 2D (KMT2D) Impending Therapeutic Target for the Management of Cancer: The Giant Rats Tail. (PubMed, J Environ Pathol Toxicol Oncol)
    Therefore, the present review serves to underline the update on recent research pertaining to KMT2D gene, that could be a potential therapeutic target in downregulating glycolytic genes such as Pgk1, Ldha, Pgam1 and Gapdh; 2, epidermal growth factor receptor tyrosine kinase (EGFR-TK ) - ERBB2, RTK-RAS signaling, RAS activator genes Rgl1, Rasgrp1, Rasgrf1, Rasgrf 2 and Rapgef5 in suppressing the tumor progression that may represent novel targeted therapy for the management of cancer. This review will facilitate to understand the gene expression that inhibits cancer progression and which could serve as a potential molecular target in understanding cancer pathogenesis.
    Preclinical • Review • Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • LDHA (Lactate dehydrogenase A) • KMT2D (Lysine Methyltransferase 2D) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase) • RASGRF1 (Ras Protein Specific Guanine Nucleotide Releasing Factor 1) • RASGRP1 (RAS Guanyl Releasing Protein 1) • RGL1 (Ral Guanine Nucleotide Dissociation Stimulator Like 1) • PGK1 (Phosphoglycerate Kinase 1)
    18d
    Cardiac rhabdomyoma: a rare feature of Birt-Hogg-Dubé syndrome. (PubMed, J Med Genet)
    We discuss this differential diagnosis and suggest that cardiac rhabdomyomas, although rare, may be associated with BHDS and potentially life threatening. Therefore, we recommend cardiac screening in newborns at risk.
    Journal
    |
    FLCN (Folliculin)
    20d
    The Interplay between von Hippel-Lindau Tumor Suppressor Gene, Lon Protease, ROS Accumulation, and Inflammation in Clear Cell Renal Cell Carcinoma. (PubMed, Curr Issues Mol Biol)
    The findings reveal increased Lon expression and ROS levels in VHL-knockdown HK-2 cells, along with elevated phospho-c-Jun N-terminal kinase (JNK) levels, emphasizing the complex interplay between VHL, Lon protease, inflammation, and ROS in kidney cell models. These insights point to potential therapeutic pathways for ccRCC.
    Journal
    |
    VHL (von Hippel-Lindau tumor suppressor) • MAPK8 (Mitogen-activated protein kinase 8)
    20d
    NPS-1034 Exerts Therapeutic Efficacy in Renal Cell Carcinoma Through Multiple Targets of MET, AXL, and TNFRSF1A Signaling in a Metastatic Model. (PubMed, Cells)
    In conclusion, we explored the therapeutic mechanism of NPS-1034 and found that it targets not only MET and AXL but also TNFRSF1A. In a lung metastatic animal model, we confirmed that NPS-1034 is a potential candidate for systemic therapy in RCC.
    Journal • IO biomarker • Metastases
    |
    AXL (AXL Receptor Tyrosine Kinase) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • GADD45A (Growth arrest and DNA-damage-inducible, alpha)
    |
    TNFRSF1A overexpression
    21d
    VHL missense mutation delineate aggressive clear cell renal cell carcinoma subtype with favorable immunotherapeutic response. (PubMed, J Immunother Cancer)
    VHL Miss mutations delineate an aggressive ccRCC subtype with distinct clinical outcomes, likely attributed to its specific oncogenic, morphologic and immunologic features.
    Journal • IO biomarker
    |
    VHL (von Hippel-Lindau tumor suppressor)
    |
    VHL mutation
    21d
    The Association Between Anti-Neoplastic Effects of Curcumin and Urogenital Cancers: A Systematic Review. (PubMed, Biomed Res Int)
    Curcumin exerts its anticancer effects on urogenital neoplasms by upregulating tumor suppressor microRNAs (miR-143, miR-145, miR-Let-7, miR-101, miR-3127, miR-3178, miR-1275, miR-3198, miR-1908, miR-770, miR-1247, miR-411, miR-34a, miR-383, miR-708, miR-483, miR-199a, miR-335, miR-503, miR-10b, miR-551a, miR-9, miR-203, miR-7110, miR-29b, and miR-126) and downregulating oncogenic microRNAs (miR-21, miR-210, miR-382, miR-654, miR-494, miR-193b, miR-671, miR-222, miR-23b, miR-664, miR-183, miR-214, miR-320a, miR-23a, miR-30a, miR-320d, miR-1285, miR-32, miR-181a, miR-205, miR-216a, miR-1246, and miR-106b). Cell proliferation is inhibited, and cell apoptosis is induced by curcumin in different urogenital cancers through suppressing oncogenic microRNAs or provoking tumor suppressor microRNAs.
    Review • Journal
    |
    MIR21 (MicroRNA 21) • MIR34A (MicroRNA 34a-5p) • MIR193B (MicroRNA 193b) • MIR1246 (MicroRNA 1246) • MIR126 (MicroRNA 126) • MIR143 (MicroRNA 143) • MIR199A (MicroRNA 199a) • MIR210 (MicroRNA 210) • MIR216A (MicroRNA 216a) • MIR23A (MicroRNA 23a) • MIR23b (MicroRNA 23b) • MIR320A (MicroRNA 320a) • MIR335 (MicroRNA 335) • MIR494 (MicroRNA 494) • MIR503 (MicroRNA 503) • MIR664A (MicroRNA 664a) • MIR106B (MicroRNA 106b) • MIR10B (MicroRNA 10b) • MIR1247 (MicroRNA 1247) • MIR127 (MicroRNA 127) • MIR145 (MicroRNA 145) • MIR181A1 (MicroRNA 181a-1) • MIR183 (MicroRNA 183) • MIR203A (MicroRNA 203a) • MIR205 (MicroRNA 205) • MIR214 (MicroRNA 214) • MIR222 (MicroRNA 222) • MIR30A (MicroRNA 30a) • MIR3178 (MicroRNA 3178) • MIR383 (MicroRNA 383) • MIR483 (MicroRNA 483) • MIR671 (MicroRNA 671) • MIR708 (MicroRNA 708)
    22d
    Differentiation fate of a stem-like CD4 T cell controls immunity to cancer. (PubMed, Nature)
    In agreement, TH1 differentiation in patients with kidney cancer predicted successful immunotherapy responses and improved progression-free survival. Together, these findings identify a stem-like CD4 T cell population that through alternative differentiation fates controls the switch between restricted and active T cell states with implications for cancer immunotherapies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule)
    22d
    Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Darzalex (daratumumab)